H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of ...
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T ...
Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Although new targets and therapies are on the horizon, current myositis treatment strategies rely ...
Please provide your email address to receive an email when new articles are posted on . Among patients with myositis, younger individuals with dermatomyositis are more likely to experience pain, while ...
The last time I spoke about Cartesian Therapeutics (RNAC) it was in a Seeking Alpha article entitled "Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data." There, I wrote about ...
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for ...
Argenx Se (ARGX) has released an update. Don't Miss our Black Friday Offers: Argenx SE is advancing the clinical development of its subcutaneous treatment, efgartigimod SC, for idiopathic inflammatory ...
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T ...
PHILADELPHIA, May 16, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results